Kyverna Therapeutics announced that all seven patients enrolled in the Phase 2 portion of its KYSA‑6 trial of miv‑cel for generalized myasthenia gravis achieved rapid, sustained improvements in the MG‑ADL and QMG scores at 24 weeks, with the benefit persisting out to one year after a single dose. The data were presented at the American Academy of Neurology Annual Meeting, which ran from April 18‑22 2026, and the company reported no new safety signals, including no high‑grade cytokine release syndrome or immune‑effector cell‑associated neurotoxicity events.
The 100 % durable response represents an unprecedented level of efficacy for a single‑dose CAR T therapy in an autoimmune disease. A drug‑free, disease‑free remission could replace the chronic immunosuppressive regimens that current gMG patients rely on, potentially transforming the standard of care and improving long‑term quality of life.
"We are pleased to share updated data for miv‑cel that continue to demonstrate the depth and durability of response across key outcome measures in patients with generalized myasthenia gravis, setting a new clinical standard," said Warner Biddle, Chief Executive Officer of Kyverna Therapeutics. "Our data reinforces confidence in miv‑cel's differentiated profile, strengthens our conviction in the ongoing Phase 3 trial, and more broadly solidifies our leadership in neuroimmunology CAR T." "Notably, today's longer‑term data demonstrate the continued deepening of response over time across multiple clinical outcome measures," said Naji Gehchan, M.D., Chief Medical and Development Officer of Kyverna Therapeutics. "These profound and unprecedented results are driven by miv‑cel's unique ability to target the disease at the source, deeply depleting B‑cells to drive an immune reset and achieve durable drug‑free, disease‑free remission for patients with generalized myasthenia gravis."
The results accelerate Kyverna’s regulatory pathway, positioning the company to file for FDA approval of miv‑cel in gMG and to launch a first‑in‑class product that could redefine treatment for an orphan disease. The company’s pipeline‑in‑a‑product strategy—applying the same CAR T platform to other B‑cell‑driven autoimmune indications such as stiff person syndrome—could unlock a broad commercial opportunity. Kyverna also presented updated data from its SPS trial at the same meeting and will discuss both programs in a conference call on April 22 2026.
Investors welcomed the data, citing the 100 % durable response and favorable safety profile as key drivers of the positive market reaction. The announcement underscores Kyverna’s leadership in neuroimmunology CAR T and signals a potential shift in the therapeutic landscape for generalized myasthenia gravis.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.